1. Poordad F, Sievert W, Mollison L, et al. All-oral, fixed-dose combination therapy with daclatasvir/asunaprevir/beclabuvir for non-cirrhotic patients with chronic HCV genotype 1 infection: UNITY-1 phase 3 SVR-12 results [LB-7]. Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, November 10, 2014.
2. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV;Ferenci;N Engl J Med,2014
3. Muir AJ, Poordad F, Lalezari J, et al. All-oral, fixed-dose combination therapy with daclatasvir/asunaprevir/beclabuvir ± ribavirin, for patients with chronic HCV genotype 1 infection and compensated cirrhosis: UNITY-2 phase 3 SVR12 results [LB-2]. Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, November 10, 2014.
4. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week combination treatment with daclatasvir (DCV) and sofosbuvir (SOF) in patients infected with HCV genotype (GT) 3: ALLY-3 phase 3 study [LB-2]. Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, November 9, 2014.
5. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection;Sulkowski;N Engl J Med,2014